Neurol. praxi. 2014;15(2):74-76

Multiple sclerosis in children

doc. MUDr. Pavol Sýkora, CSc.
Klinika detskej neurológie LF UK a DFNsP, Bratislava

In 2–5% of patients, multiple sclerosis (MS) develops before the age of 16 years. The incidence of the paediatric form of MS is 0.3/100,000 in Germany. The aetiopathogenesis of MS involves genetic and environmental factors, previous infectious diseases, and immune system alterations. In children, the disease is rare and specific mechanisms in the immune and central nervous systems are implied that inhibit the manifestation of MS. The diagnosis of MS is established based on the clinical signs of a second attack along with MRI of the brain and cerebrospinal fluid analysis. The treatment of MS in children employs the principles of that in adults. Early manifestation of the disease results in earlier disability. sclerosis treatment.

Keywords: demyelinating diseases of the CNS, ADEM – acute disseminated encephalomyelitis, multiple sclerosis in children, multiple

Published: May 10, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sýkora P. Multiple sclerosis in children. Neurol. praxi. 2014;15(2):74-76.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y. Intravenous imunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo controled trial. Arch Neurol. 2004; 61: 1515-1520. Go to original source... Go to PubMed...
    2. Banwel B, Bar-Or A, Arnold DL, 2. Sadovnick D, Narayanan S, McGowan M, O'Mahony J, Magalhaes S, Hanwell H, Vieth R, Tellier R, Vincent T, Disanto G, Ebers G, Wambera K, Connolly MB, Yager J, Mah JK, Booth F, Sebire G, Callen D, Meaney B, Dilenge ME, Lortie A, Pohl D, Doja A, Venketaswaran S, Levin S, Macdonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Cooper P, Grand'maison F, Baird JB, Bhan V, Marrie RA. Clinical, environmental and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011; 10: 436-445. Go to original source... Go to PubMed...
    3. Bauer HJ, Hanefeld FA. Multiple sclerosis im Kindesalter. In: Hanafeld FA, Rating D, Christen HJ, eds. Aktuelle Neuropädiatrie. Berlin: Springer-Verlag; 1989: 285-98. Go to original source...
    4. Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000; 123(12): 2407-2422. Go to original source... Go to PubMed...
    5. Julian L, Serafin D, Charvet L, Ackerson J, Benedict R, Braaten E, Brown T, O'Donnell E, Parrish J, Preston T, Zaccariello M, Belman A, Chitnis T, Gorman M, Ness J, Patterson M, Rodriguez M, Waubant E, Weinstock-Guttman B, Yeh A, Krupp LB; Network of Pediatric MS Centers of Excellence. Cognitive impairment occur in children and adolescents with multiple sclerosis: results from Unites States Network. J. Child Neurol. 2013; 28(1): 102-107. Go to original source... Go to PubMed...
    6. Krupp BL, Banwell B, Tenembaum S. For the International Pediatric MS Study Group: Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007; 68(suppl 2): S7-S12. Go to original source... Go to PubMed...
    7. Masterman T, Ligers A, Olsson T, Anderson M, Olerup O, Hillert J. HLA-DR15 is associated wit early age at onset in multiple sclerosis. Ann neurol. 2000; 48: 211-219. Go to original source... Go to PubMed...
    8. Mikaleoff Y, Suissa S, Valee L, Lubetzki C, Ponsot G, Confavreux C, Tardieu M; KIDMUS Study Group. 8. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pedait. 2004; 144: 246-252. Go to original source... Go to PubMed...
    9. Ness JM, Chabas D, Sadovnick AD, Banwell B, Weinstock-Guttman B. For International Pediatric MS Study Group. Clinical features of children and adolescents with multiple sclerosis. Neurology. 2007; 68(16suppl 2): S37-45. Go to original source... Go to PubMed...
    10. Pohl D, Waubant E, Banwell B, Chabas D, Chitnis, Weinsto-Guttman B, Tenembaum S; International Pediatric MS Study Group. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007; 68(Supp12): S54-65. Go to original source... Go to PubMed...
    11. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C. Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with chidlhood onset. N Eng J Med. 2007; 356(25): 2603-2613. Go to original source... Go to PubMed...
    12. Rubin JP, Kunty NL. Diagnostic criteria for pediatric multiple sclerosis. Cur Neurol Neurosci Re. 2013; 13: 344-354. Go to original source... Go to PubMed...
    13. Sadaka Z, Verhey LH, Shroff MM, et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol. 2012; 72: 211-223. Go to original source... Go to PubMed...
    14. Sýkora P. Akútne a chronické demyelinizujúce ochorenia mozgu a miechy. Pediatr. Prax. 2008; 4: 227-228.
    15. Vargas-Lowy D, Chitnis T. Pathogenesis of pediatric multiple sclerosis. J.Child. Neurol. 2012; 27(11) 1394-1407. Go to original source... Go to PubMed...
    16. Yeh EA, Weinstock-Guttman B, Ramanathan M, Ramasany DP, Willis L, Cox JL, Zavadinov R. Magnetic resonance imaging characteristic of children and adults with paediatric-onset multiple sclerosis. Brain. 2009; 132(PT12): 3392-3400. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.